GILEAD SCIENCES, INC. Equity Securities, FV-NI, Unrealized Loss
GILEAD SCIENCES, INC. (GILD) reported Equity Securities, FV-NI, Unrealized Loss of $284.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesFvNiUnrealizedLoss · last filed 2025-02-28
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2024-03-31 was $15.00M, a 91.98% decline year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-12-31 was -$296.00M, a 436.36% decline year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-09-30 was $168.00M, a 14.72% decline year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for fiscal 2024 was $284.00M, a 373.33% increase from fiscal 2023.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for fiscal 2023 was $60.00M, a 91.23% decline from fiscal 2022.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for fiscal 2022 was $684.00M, a 5.72% increase from fiscal 2021.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized loss for fiscal 2021 was $647.00M, a 61.94% decline from fiscal 2020.
| Period end | Equity Securities, FV-NI, Unrealized Loss 3 month | Equity Securities, FV-NI, Unrealized Loss 3 month as first filed | Equity Securities, FV-NI, Unrealized Loss 6 month | Equity Securities, FV-NI, Unrealized Loss 9 month | Equity Securities, FV-NI, Unrealized Loss 12 month | Equity Securities, FV-NI, Unrealized Loss 12 month as first filed |
|---|---|---|---|---|---|---|
| 2024-12-31 | $284.00M 10-K · filed 2025-02-28 | |||||
| 2024-03-31 | $15.00M 10-Q · filed 2024-05-08 | -$281.00M derived: sum of 2 quarters · filed 2025-02-28 | -$113.00M derived: sum of 3 quarters · filed 2025-02-28 | -$113.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-12-31 | -$296.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$128.00M derived: sum of 2 quarters · filed 2025-02-28 | -$128.00M derived: sum of 3 quarters · filed 2025-02-28 | $60.00M 10-K · filed 2025-02-28 | ||
| 2023-09-30 | $168.00M 10-Q · filed 2023-11-07 | $168.00M derived: sum of 2 quarters · filed 2023-11-07 | $356.00M 10-Q · filed 2023-11-07 | $443.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $187.00M 10-Q · filed 2023-08-04 | $275.00M derived: sum of 3 quarters · filed 2025-02-28 | $472.00M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | $187.00M 10-Q · filed 2024-05-08 | $256.00M 10-Q · filed 2023-05-03 | $275.00M derived: sum of 2 quarters · filed 2025-02-28 | $472.00M derived: sum of 3 quarters · filed 2025-02-28 | $775.00M derived: sum of 4 quarters · filed 2025-02-28 | |
| 2022-12-31 | $88.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $285.00M derived: sum of 2 quarters · filed 2025-02-28 | $588.00M derived: sum of 3 quarters · filed 2025-02-28 | $684.00M 10-K · filed 2025-02-28 | $657.00M 10-K · filed 2023-02-22 | |
| 2022-09-30 | $197.00M 10-Q · filed 2023-11-07 | $500.00M derived: sum of 2 quarters · filed 2023-11-07 | $596.00M 10-Q · filed 2023-11-07 | $576.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-06-30 | $303.00M 10-Q · filed 2023-08-04 | $399.00M 10-Q · filed 2023-08-04 | $379.00M derived: sum of 3 quarters · filed 2024-02-23 | $521.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2022-03-31 | $96.00M 10-Q · filed 2023-05-03 | $76.00M derived: sum of 2 quarters · filed 2024-02-23 | $218.00M derived: sum of 3 quarters · filed 2024-02-23 | $392.00M derived: sum of 4 quarters · filed 2024-02-23 | ||
| 2021-12-31 | -$20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $122.00M derived: sum of 2 quarters · filed 2024-02-23 | $296.00M derived: sum of 3 quarters · filed 2024-02-23 | $647.00M 10-K · filed 2024-02-23 | $610.00M 10-K · filed 2022-02-23 | |
| 2021-09-30 | $142.00M 10-Q · filed 2022-11-02 | $316.00M derived: sum of 2 quarters · filed 2022-11-02 | $667.00M 10-Q · filed 2022-11-02 | $1.32B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $174.00M 10-Q · filed 2022-08-08 | $525.00M 10-Q · filed 2022-08-08 | $1.18B derived: sum of 3 quarters · filed 2023-02-22 | $2.14B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $351.00M 10-Q · filed 2022-05-04 | $1.00B derived: sum of 2 quarters · filed 2023-02-22 | $1.97B derived: sum of 3 quarters · filed 2023-02-22 | $1.77B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2020-12-31 | $654.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.62B derived: sum of 2 quarters · filed 2023-02-22 | $1.42B derived: sum of 3 quarters · filed 2023-02-22 | $1.70B 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $964.00M 10-Q · filed 2020-11-04 | $763.00M derived: sum of 2 quarters · filed 2020-11-04 | $1.05B 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | -$201.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $82.00M 10-Q · filed 2020-08-06 | ||||
| 2020-03-31 | $283.00M 10-Q · filed 2020-05-06 | |||||
| 2018-09-30 | -$168.00M 10-Q · filed 2018-11-06 | -$104.00M derived: sum of 2 quarters · filed 2019-08-06 | -$149.00M 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $64.00M 10-Q · filed 2019-08-06 | $19.00M 10-Q · filed 2019-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |